non-small cell lung cancer

Research in Review
Statin Use May Improve Survival in Patients With Lung Cancer
07/11/2016
JCP Editors
Statin use may be associated with improved survival among patients with stage IV non-small cell lung cancer (NSCLC), according to findings from a study published in the journal Lung. Prior studies have shown that...
Statin use may be associated with improved survival among patients with stage IV non-small cell lung cancer (NSCLC), according to findings from a study published in the journal Lung. Prior studies have shown that...
Statin...
07/11/2016
Journal of Clinical Pathways
New Treatment Improves Response in ALK-Positive NSCLC
06/14/2016
JCP Editors
Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase...
Patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease has progressed while on crizotinib (CRZ) may experience improved response rates when treated with the investigational tyrosine kinase...
...
06/14/2016
Journal of Clinical Pathways
Drug Combination Reduces Adverse Events and Need for Dose Reductions
06/02/2016
JCP Editors
The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the...
The addition of plinabulin to non-small cell lung cancer (NSCLC) treatment with docetaxel may reduce the frequency of adverse events and help prevent dose reductions due to toxicity, according to an abstract at the...
The...
06/02/2016
Journal of Clinical Pathways
Research in Review
Review of EGFR Mutation-Positive NSCLC Drugs Identifies Optimal Treatments
06/02/2016
JCP Editors
A review of treatments for non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor mutation positive (EGFR M+) has identified which therapies are the most effective at managing disease symptoms...
A review of treatments for non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor mutation positive (EGFR M+) has identified which therapies are the most effective at managing disease symptoms...
A...
06/02/2016
Journal of Clinical Pathways
Research in Review
Weight Gain a Sign of Successful Treatment in Patients With NSCLC
05/24/2016
JCP Editors
Weight gain may be an indicator of successful treatment for patients with non-small cell lung cancer (NSCLC), according to findings from a recently published article. Past studies have linked unintentional weigh...
Weight gain may be an indicator of successful treatment for patients with non-small cell lung cancer (NSCLC), according to findings from a recently published article. Past studies have linked unintentional weigh...
Weight...
05/24/2016
Journal of Clinical Pathways
Research in Review
Novel Biomarker Predicts Treatment Response in NSCLC
05/19/2016
JCP Editors
A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to...
A study of SMARCA/BRG1 expression in patients with non-small cell lung (NSCLC) cancer has found that it is a significant indicator of prognosis and a novel predictive biomarker for increased sensitivity to...
A...
05/19/2016
Journal of Clinical Pathways
Research Reports
Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations
05/06/2016
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
...
05/06/2016
Journal of Clinical Pathways
SBRT for Patients With NSCLC Linked to Higher Rates of Non-Cancer Death
05/04/2016
JCP Editors
Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at...
Using stereotactic body radiation therapy (SBRT) to treat patients with non-small cell lung cancer (NSCLC) may slightly increase the risk of dying from a cause other than cancer, according to research presented at...
Using...
05/04/2016
Journal of Clinical Pathways
NCCN Announces Changes to Guidelines for NSCLC
04/06/2016
JCP Editors
New guidelines for non-small cell lung cancer (NSCLC) recommend testing for epidermal growth factor receptor (EGRF) mutations as a part of routine care for patients diagnosed with non-small cell lung cancer (NSCLC),...
New guidelines for non-small cell lung cancer (NSCLC) recommend testing for epidermal growth factor receptor (EGRF) mutations as a part of routine care for patients diagnosed with non-small cell lung cancer (NSCLC),...
New...
04/06/2016
Journal of Clinical Pathways
Research in Review
Atezolizumab Safely Improves Survival for Patients Previously Treated for Non-Small Cell Lung Cancer
04/01/2016
JCP Editors
Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...
Atezolizumab may be a safe and effective option for patients with non-small cell lung cancer (NSCLC) who have progressed on post-platinum chemotherapy, according to results from a phase 2 randomized controlled...
...
04/01/2016
Journal of Clinical Pathways

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use